Unfortunately, we do not yet have results in other tumors, but several trials are ongoing, especially in CRC in different stages of recruiting, also with anti-PD-1/PD-L1 and/or anti-LAG3 antibodies as single agents or in combination (Table 2). Here, LAG3 is linked to colorectal carcinoma.